call Toll Free (US/Canada): +1 866 658 6826 | call+1 425 320 4776 | call (UK): +44 1865 60 0662 | call (Ind): +91 9096278110 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Non Hodgkin Lymphoma Therapeutics Market
Inquire Before Buying Request for Sample

Non Hodgkin Lymphoma Therapeutics Market

Home Healthcare And Pharmaceutical Non Hodgkin Lymphoma Therapeutics Market

Non-Hodgkin Lymphoma Therapeutics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019–2030, Segmented By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation); By Drug Class (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Antimetabolites); By Route of Administration (Oral, Intravenous, Subcutaneous, Intrathecal); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings); By Region (North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA))

  • Published Date: July 2024
  • Report ID: BWC24515
  • Available Format: PDF
  • Page: 400

Report Overview

Increasing prevalence of non-Hodgkin lymphoma, advancements in treatment options, and growing awareness about early diagnosis and innovative therapies are key driving factors of Global Non-Hodgkin Lymphoma Therapeutics Market during the forecast period between 2024 and 2030.

Global Non-Hodgkin Lymphoma Therapeutics Market – Industry Trends & Forecast Report, 2030

Global Non-Hodgkin Lymphoma Therapeutics Market size was estimated at USD 12.3 billion in 2023. During the forecast period between 2024 and 2030, Global Non-Hodgkin Lymphoma Therapeutics Market size is expected to expand at a CAGR of 8.90% reaching a value of USD 20.5 billion by 2030. Global Non-Hodgkin Lymphoma Therapeutics Market is driven by rising incidence rates of the disease, advancements in diagnostic techniques, and the development of innovative treatments, including targeted therapies and immunotherapies. Increased healthcare expenditure, growing awareness about early diagnosis, and supportive government initiatives also contribute to market growth. Additionally, an aging global population, a higher prevalence of immunodeficiency disorders, and significant investments in research and development by pharmaceutical companies further propel the market expansion. These factors collectively enhance the availability and efficacy of therapeutic options for patients with non-Hodgkin lymphoma.

Non-Hodgkin Lymphoma Therapeutics Market

Non-Hodgkin Lymphoma (NHL) Therapeutics – Overview

Non-Hodgkin Lymphoma (NHL) therapeutics encompass a range of treatments including chemotherapy, radiation therapy, targeted therapy, immunotherapy, and stem cell transplants. Chemotherapy uses drugs to kill cancer cells, while radiation therapy employs high-energy rays. Targeted therapy focuses on specific molecules involved in cancer growth, and immunotherapy boosts the body's immune system to fight cancer. Stem cell transplants restore healthy blood cells after intensive treatment. Advances in these areas, particularly in targeted and immunotherapies, have significantly improved survival rates and quality of life for NHL patients, offering more personalized and effective treatment options.

Global Non-Hodgkin Lymphoma Therapeutics Market

Growth Drivers

Increasing Adoption of Targeted Therapies and Immunotherapy

Global Non-Hodgkin Lymphoma Therapeutics Market is experiencing robust growth, propelled by the rising adoption of targeted therapies and immunotherapy. These advanced treatments offer precision in attacking cancer cells while minimizing damage to healthy tissues, leading to improved patient outcomes. Breakthroughs in monoclonal antibodies, CAR T-cell therapy, and checkpoint inhibitors are revolutionizing care standards. As healthcare providers increasingly implement these innovative therapies, supported by ongoing research and favorable regulatory environments, the market is poised for significant expansion, addressing the growing prevalence of non-Hodgkin lymphoma worldwide.

Challenges

High Cost of Treatments

The growth of Global Non-Hodgkin Lymphoma Therapeutics Market is facing significant challenges due to the high cost of treatments. Advanced therapies, while effective, come with steep price tags, making them inaccessible for many patients and straining healthcare budgets. The financial barrier is slowing market growth, as both patients and healthcare providers struggle to afford cutting-edge treatments. Additionally, the economic burden is prompting calls for more affordable therapeutic options and increased support for healthcare systems to ensure broader access to these life-saving drugs.

Impact of Escalating Geopolitical Tensions on Global Non-Hodgkin Lymphoma Therapeutics Market

Global Non-Hodgkin Lymphoma Therapeutics Market is facing significant challenges posed by intensifying geopolitical tensions among major countries across the regions. For instance, disruptions in the supply chain due to prolonging conflicts, such as the Russia-Ukraine war, can delay drug production and distribution. Trade restrictions and sanctions hinder the availability of essential raw materials and pharmaceuticals. For instance, the COVID-19 pandemic exacerbated these issues, highlighting the vulnerability of global supply chains. Additionally, increased defense spending can divert funds from healthcare, affecting research and development investments. The uncertainty caused by geopolitical instability may also lead to fluctuating market conditions, affecting investor confidence and funding for new therapies. Thus, maintaining a stable geopolitical environment is crucial for ensuring continuous advancements in and the availability of lymphoma treatments.

Global Non-Hodgkin Lymphoma Therapeutics Market

Segmental Coverage

Global Non-Hodgkin Lymphoma Therapeutics Market – By Therapy Type

Based on therapy type, Global Non-Hodgkin Lymphoma Therapeutics Market is divided into Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, and Stem Cell Transplantation segments. The immunotherapy type is the largest segment in Global Non-Hodgkin Lymphoma Therapeutics Market. The segment's dominance is attributed to its effectiveness in targeting cancer cells with minimal damage to surrounding healthy tissue, the increasing adoption of immunotherapeutic agents, and advancements in monoclonal antibodies and CAR T-cell therapies. Immunotherapy has shown promising results in improving patient outcomes and survival rates, making it a preferred choice among healthcare providers. The growing research and development activities, coupled with substantial investments, further bolster the prominence of the immunotherapy segment in the global market.

Non-Hodgkin Lymphoma Therapeutics Market Size

Global Non-Hodgkin Lymphoma Therapeutics Market – By Drug Class

On the basis of drug class, Global Non-Hodgkin Lymphoma Therapeutics Market is divided into Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Histone Deacetylase Inhibitors, and Antimetabolites segments. The monoclonal antibodies drug class holds the highest market share in Global Non-Hodgkin Lymphoma Therapeutics Market. The segment’s dominance is due to their high efficacy and targeted action, which significantly improve patient outcomes. Monoclonal antibodies have become a cornerstone in lymphoma treatment, offering specific targeting of cancer cells with fewer side effects compared to traditional chemotherapy. The widespread adoption and ongoing development of novel monoclonal antibodies contribute to the segment's leading position in the market, reflecting the continuous advancements and clinical success in treating various subtypes of non-Hodgkin lymphoma.

Non-Hodgkin Lymphoma Therapeutics Market Growth

Global Non-Hodgkin Lymphoma Therapeutics Market – By End User

By end user, Global Non-Hodgkin Lymphoma Therapeutics Market is divided into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Homecare Settings segments. The hospital segment dominates the market, offering comprehensive care and specialized treatments for non-Hodgkin lymphoma patients. Hospitals provide a range of services including diagnosis, chemotherapy, radiation therapy, and supportive care, making them pivotal in managing the disease. With their advanced infrastructure, multidisciplinary teams, and access to cutting-edge treatments, hospitals play a crucial role in addressing the complex needs of non-Hodgkin lymphoma patients, positioning them as the primary setting for treatment and management of this condition.

Non-Hodgkin Lymphoma Therapeutics Market Share

Global Non-Hodgkin Lymphoma Therapeutics Market – By Region

Geographically, Global Non-Hodgkin Lymphoma Therapeutics Market is divided into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), and Middle East and Africa (MEA) region. The leading region in Global Non-Hodgkin Lymphoma Therapeutics Market is North America, followed by Europe. These regions typically exhibit advanced healthcare infrastructure, extensive research facilities, and higher healthcare spending. North America, encompassing the United States and Canada, often leads in terms of market size due to factors like a higher prevalence of non-Hodgkin lymphoma cases and greater accessibility to innovative treatments. Europe, with its developed healthcare systems and significant investments in research and development, also contributes substantially to the market. Together, these regions dominate Global Non-Hodgkin Lymphoma Therapeutics Market.

Competitive Landscape

Major players in Global Non-Hodgkin Lymphoma Therapeutics Market include AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Seagen Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals Inc., Eli Lilly and Company, Spectrum Pharmaceuticals Inc., Bristol Myers Squibb Co., and AbbVie. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

  • In May 2023 - The US FDA granted approval for the investigational new drug (IND) application of SIRPant Immunotherapeutics for the initiation of a first-in-human Phase I clinical trial to treat relapsed refractory non-Hodgkin lymphoma.

  • In May 2023 – AbbVie obtained the US FDA approval for its EPKINLY, a T-cell-engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2023

Base Year – 2023

Estimated Year – 2024

Forecast Period – 2024–2030

Facts Covered

Revenue in USD Billion 

Market Coverage

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Product/Service Segmentation

Therapy Type, Drug Class, Route of Administration, End User, Region

Key Players

AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Seagen Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals Inc., Eli Lilly and Company, Spectrum Pharmaceuticals Inc., Bristol Myers Squibb Co., AbbVie

 

By Therapy Type

    • Chemotherapy

    • Immunotherapy

    • Targeted Therapy

    • Radiation Therapy

    • Stem Cell Transplantation

By Drug Class

    • Monoclonal Antibodies

    • Tyrosine Kinase Inhibitors

    • Proteasome Inhibitors

    • Histone Deacetylase Inhibitors

    • Antimetabolites

By Route of Administration

    • Oral

    • Intravenous

    • Subcutaneous

    • Intrathecal

By End User

    • Hospitals

    • Specialty Clinics

    • Ambulatory Surgical Centers

    • Homecare Settings

By Region

    • North America

    • Europe

    • Asia Pacific (APAC)

    • Latin America (LATAM)

    • Middle East and Africa (MEA)

  1. Research Framework
    1. Research Objective
    2. Therapy Type Overview
    3. Market Segmentation
  2. Executive Summary
  3. Global Non-Hodgkin Lymphoma Therapeutics Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Rising Prevalence of Non-Hodgkin Lymphoma
        2. Increasing Adoption of Targeted Therapies and Immunotherapy
        3. Growing Geriatric Population
      2. Restraints
        1. High Cost of Treatments
        2. Limited Reimbursement Policies
        3. Stringent Regulatory Approval Process
      3. Opportunities
        1. Development of Novel Drug Combinations
        2. Emerging Markets with Untapped Potential
        3. Rising Focus on Personalized Medicine
      4. Challenges
        1. Drug Resistance in Relapsed/Refractory Cases
        2. Side Effects Associated with Therapies
        3. Maintaining Sustainability in Healthcare Systems
    3. Technological Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. Global Non-Hodgkin Lymphoma Therapeutics Market: Marketing Strategies
  5. Global Non-Hodgkin Lymphoma Therapeutics Market: Pricing Analysis
  6. Global Non-Hodgkin Lymphoma Therapeutics Market: Geography Analysis
    1. Global Non-Hodgkin Lymphoma Therapeutics Market, Geographical Analysis, 2023
    2. Global Non-Hodgkin Lymphoma Therapeutics Market Attractiveness Analysis, 2024–2030
  7. Global Non-Hodgkin Lymphoma Therapeutics Market Overview
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Therapy Type
        1. Chemotherapy
        2. Immunotherapy
        3. Targeted Therapy
        4. Radiation Therapy
        5. Stem Cell Transplantation
      2. By Drug Class
        1. Monoclonal Antibodies
        2. Tyrosine Kinase Inhibitors
        3. Proteasome Inhibitors
        4. Histone Deacetylase Inhibitors
        5. Antimetabolites
      3. By Route of Administration
        1. Oral
        2. Intravenous
        3. Subcutaneous
        4. Intrathecal
      4. By End User
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Homecare Settings
      5. By Country
        1. North America
        2. Europe
        3. Asia Pacific (APAC)
        4. Latin America (LATAM)
        5. Middle East and Africa (MEA)
  8. North America Non-Hodgkin Lymphoma Therapeutics Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Therapy Type
      2. By Drug Class
      3. By Route of Administration
      4. By End User
      5. By Country
        1. United States
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        2. Canada
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
  9. Europe Non-Hodgkin Lymphoma Therapeutics Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Therapy Type
      2. By Drug Class
      3. By Route of Administration
      4. By End User
      5. By Country
        1. Germany
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        2. United Kingdom
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        3. Italy
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        4. France
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        5. Spain
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        6. Belgium
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        7. Russia
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        8. The Netherlands
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        9. Rest of Europe
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
  10. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Therapy Type
      2. By Drug Class
      3. By Route of Administration
      4. By End User
      5. By Country
        1. China
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        2. India
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        3. Japan
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        4. South Korea
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        5. Australia & New Zealand
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        6. Indonesia
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        7. Malaysia
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        8. Singapore
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        9. Vietnam
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        10. Rest of APAC
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
  11. Latin America Non-Hodgkin Lymphoma Therapeutics Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Therapy Type
      2. By Drug Class
      3. By Route of Administration
      4. By End User
      5. By Country
        1. Brazil
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        2. Mexico
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        3. Argentina
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        4. Peru
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        5. Rest of LATAM
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
  12. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Therapy Type
      2. By Drug Class
      3. By Route of Administration
      4. By End User
      5. By Country
        1. Saudi Arabia
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        2. UAE
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        3. Qatar
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        4. Kuwait
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        5. South Africa
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        6. Nigeria
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        7. Algeria
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
        8. Rest of MEA
          1. By Therapy Type
          2. By Drug Class
          3. By Route of Administration
          4. By End User
  13. Competitive Landscape
    1. List of Key Players and Their Drive Types
    2. Global Non-Hodgkin Lymphoma Therapeutics Market Share Analysis, 2023
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  14. Global Non-Hodgkin Lymphoma Therapeutics Market: Import & Export
  15. Impact of Escalating Geopolitical Tensions on Global Non-Hodgkin Lymphoma Therapeutics Market
  16. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
    1. AstraZeneca Plc
    2. Bayer AG
    3. F. Hoffmann-La Roche Ltd
    4. GlaxoSmithKline Plc
    5. Seagen Inc.
    6. Takeda Pharmaceutical Company Limited
    7. Janssen Pharmaceuticals Inc.
    8. Eli Lilly and Company
    9. Spectrum Pharmaceuticals Inc.
    10. Bristol Myers Squibb Co.
    11. AbbVie
    12. Other Prominent Players
  17. Key Strategic Recommendations
  18. Research Methodology
    1.  Qualitative Research
      1.  Primary & Secondary Research
    2.  Quantitative Research
    3.  Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
    4.  Breakdown of Primary Research Respondents, By Region
    5.  Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

 

List of Figures

Figure 1       Global Non-Hodgkin Lymphoma Therapeutics Segmentation       

Figure 2       Global Non-Hodgkin Lymphoma Therapeutics Market Value (USD Billion) Chain Analysis      

Figure 3       Company Market Share Analysis, 2023

Figure 4       Global Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 5       Global Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 6       Global Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 7       Global Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 8       Global Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 9       Global Non-Hodgkin Lymphoma Therapeutics Market Share, By Region, By Value (USD Billion), 2019–2030

Figure 10     North America Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 11     North America Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030     

Figure 12     North America Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 13     North America Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 14     North America Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030    

Figure 15     North America Non-Hodgkin Lymphoma Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 16     United States Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 17     United States Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030     

Figure 18     United States Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 19     United States Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 20     United States Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 21     Canada Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 22     Canada Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 23     Canada Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 24     Canada Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 25     Canada Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 26     Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 27     Europe Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 28     Europe Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 29     Europe Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 30     Europe Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 31     Europe Non-Hodgkin Lymphoma Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 32     Germany Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 33     Germany Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 34     Germany Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 35     Germany Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 36     Germany Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 37     United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 38     United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030     

Figure 39     United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 40     United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 41     United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030    

Figure 42     Italy Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 43     Italy Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 44     Italy Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 45     Italy Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 46     Italy Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 47     France Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 48     France Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 49     France Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 50     France Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 51     France Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 52     Spain Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 53     Spain Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 54     Spain Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 55     Spain Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 56     Spain Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 57     Belgium Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 58     Belgium Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 59     Belgium Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 60     Belgium Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 61     Belgium Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 62     Russia Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 63     Russia Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 64     Russia Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 65     Russia Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 66     Russia Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 67     The Netherlands Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030     

Figure 68     The Netherlands Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 69     The Netherlands Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 70     The Netherlands Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030    

Figure 71     Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 72     Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030     

Figure 73     Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 74     Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 75     Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030    

Figure 76     Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 77     Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030    

Figure 78     Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 79     Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 80     Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 81     Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 82     China Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 83     China Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 84     China Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 85     China Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 86     China Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 87     India Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 88     India Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 89     India Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 90     India Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 91     India Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 92     Japan Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 93     Japan Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 94     Japan Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 95     Japan Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 96     Japan Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 97     South Korea Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 98     South Korea Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030    

Figure 99     South Korea Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 100   South Korea Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 101   South Korea Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 102   Australia & New Zealand Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030

Figure 103   Australia & New Zealand Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030  

Figure 104   Australia & New Zealand Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030      

Figure 105   Australia & New Zealand Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030      

Figure 106   Australia & New Zealand Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 107   Indonesia Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 108   Indonesia Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030    

Figure 109   Indonesia Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 110   Indonesia Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 111   Indonesia Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 112   Malaysia Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 113   Malaysia Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 114   Malaysia Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 115   Malaysia Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 116   Malaysia Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 117   Singapore Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 118   Singapore Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030    

Figure 119   Singapore Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 120   Singapore Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 121   Singapore Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 122   Vietnam Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 123   Vietnam Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 124   Vietnam Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 125   Vietnam Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 126   Vietnam Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 127   Rest of APAC Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 128   Rest of APAC Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030    

Figure 129   Rest of APAC Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 130   Rest of APAC Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 131   Rest of APAC Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 132   Latin America Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 133   Latin America Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030     

Figure 134   Latin America Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 135   Latin America Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 136   Latin America Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 137   Latin America Non-Hodgkin Lymphoma Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 138   Brazil Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 139   Brazil Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 140   Brazil Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 141   Brazil Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 142   Brazil Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 143   Mexico Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 144   Mexico Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 145   Mexico Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 146   Mexico Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 147   Mexico Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 148   Argentina Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 149   Argentina Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030    

Figure 150   Argentina Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 151   Argentina Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 152   Argentina Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 153   Peru Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 154   Peru Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 155   Peru Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 156   Peru Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 157   Peru Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 158   Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 159   Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030     

Figure 160   Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 161   Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 162   Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030    

Figure 163   Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030

Figure 164   Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030  

Figure 165   Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 166   Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030      

Figure 167   Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030      

Figure 168   Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 169   Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 170   Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030    

Figure 171   Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 172   Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 173   Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Share, By Distribution Horsepower, By Value (USD Billion), 2019–2030    

Figure 174   UAE Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 175   UAE Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 176   UAE Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 177   UAE Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 178   UAE Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 179   Qatar Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 180   Qatar Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 181   Qatar Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 182   Qatar Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 183   Qatar Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 184   Kuwait Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 185   Kuwait Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 186   Kuwait Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 187   Kuwait Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 188   Kuwait Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 189   South Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 190   South Africa Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030    

Figure 191   South Africa Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 192   South Africa Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 193   South Africa Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 194   Nigeria Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 195   Nigeria Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 196   Nigeria Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 197   Nigeria Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 198   Nigeria Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 199   Algeria Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Figure 200   Algeria Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030

Figure 201   Algeria Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030

Figure 202   Algeria Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 203   Algeria Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030

Figure 204   Rest of MEA Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Figure 205   Rest of MEA Non-Hodgkin Lymphoma Therapeutics Market Share, By Therapy Type, By Value (USD Billion), 2019–2030    

Figure 206   Rest of MEA Non-Hodgkin Lymphoma Therapeutics Market Share, By Drug Class, By Value (USD Billion), 2019–2030    

Figure 207   Rest of MEA Non-Hodgkin Lymphoma Therapeutics Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 208   Rest of MEA Non-Hodgkin Lymphoma Therapeutics Market Share, By End User, By Value (USD Billion), 2019–2030         

 

List of Tables

 

Table 1         Global Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 2         Global Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 3         Global Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 4         Global Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 5         Global Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 6         Global Non-Hodgkin Lymphoma Therapeutics Market Size, By Region, By Value (USD Billion), 2019–2030

Table 7         North America Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 8         North America Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 9         North America Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030    

Table 10       North America Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 11       North America Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 12       North America Non-Hodgkin Lymphoma Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2030

Table 13       United States Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 14       United States Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 15       United States Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 16       United States Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 17       United States Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 18       Canada Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 19       Canada Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 20       Canada Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 21       Canada Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 22       Canada Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 23       Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 24       Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 25       Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 26       Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 27       Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 28       Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2030

Table 29       Germany Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 30       Germany Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 31       Germany Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 32       Germany Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 33       Germany Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 34       United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 35       United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030     

Table 36       United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030    

Table 37       United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 38       United Kingdom Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030    

Table 39       Italy Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 40       Italy Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 41       Italy Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 42       Italy Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 43       Italy Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 44       France Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 45       France Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 46       France Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 47       France Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 48       France Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 49       Spain Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 50       Spain Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 51       Spain Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 52       Spain Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 53       Spain Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 54       Belgium Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 55       Belgium Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 56       Belgium Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 57       Belgium Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 58       Belgium Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 59       Russia Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 60       Russia Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 61       Russia Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 62       Russia Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 63       Russia Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 64       The Netherlands Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030     

Table 65       The Netherlands Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030    

Table 66       The Netherlands Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 67       The Netherlands Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030    

Table 68       Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 69       Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 70       Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030    

Table 71       Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 72       Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 73       Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 74       Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 75       Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 76       Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 77       Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 78       Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2030

Table 79       China Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 80       China Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 81       China Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 82       China Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 83       China Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 84       India Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 85       India Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 86       India Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 87       India Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 88       India Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 89       Japan Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 90       Japan Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 91       Japan Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 92       Japan Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 93       Japan Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 94       South Korea Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 95       South Korea Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 96       South Korea Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 97       South Korea Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 98       South Korea Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 99       Australia & New Zealand Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030

Table 100     Australia & New Zealand Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030  

Table 101     Australia & New Zealand Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030      

Table 102     Australia & New Zealand Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030      

Table 103     Australia & New Zealand Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030      

Table 104     Indonesia Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 105     Indonesia Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 106     Indonesia Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 107     Indonesia Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 108     Indonesia Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 109     Malaysia Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 110     Malaysia Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 111     Malaysia Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 112     Malaysia Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 113     Malaysia Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 114     Singapore Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 115     Singapore Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 116     Singapore Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 117     Singapore Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 118     Singapore Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 119     Vietnam Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 120     Vietnam Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 121     Vietnam Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 122     Vietnam Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 123     Vietnam Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 124     Rest of APAC Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 125     Rest of APAC Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 126     Rest of APAC Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 127     Rest of APAC Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 128     Rest of APAC Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 129     Latin America Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 130     Latin America Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 131     Latin America Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030    

Table 132     Latin America Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 133     Latin America Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 134     Latin America Non-Hodgkin Lymphoma Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2030

Table 135     Brazil Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 136     Brazil Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 137     Brazil Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 138     Brazil Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 139     Brazil Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 140     Mexico Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 141     Mexico Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 142     Mexico Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 143     Mexico Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 144     Mexico Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 145     Argentina Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 146     Argentina Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 147     Argentina Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 148     Argentina Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 149     Argentina Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 150     Peru Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 151     Peru Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 152     Peru Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 153     Peru Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 154     Peru Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 155     Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 156     Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 157     Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030    

Table 158     Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 159     Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 160     Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030

Table 161     Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030     

Table 162     Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030    

Table 163     Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030      

Table 164     Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030      

Table 165     Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2030    

Table 166     Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 167     Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 168     Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 169     Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 170     Saudi Arabia Non-Hodgkin Lymphoma Therapeutics Market Size, By Distribution Horsepower, By Value (USD Billion), 2019–2030    

Table 171     UAE Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 172     UAE Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 173     UAE Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 174     UAE Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030    

Table 175     UAE Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030        

Table 176     Qatar Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 177     Qatar Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 178     Qatar Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 179     Qatar Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 180     Qatar Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 181     Kuwait Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 182     Kuwait Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 183     Kuwait Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 184     Kuwait Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 185     Kuwait Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 186     South Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 187     South Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 188     South Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 189     South Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 190     South Africa Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 191     Nigeria Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 192     Nigeria Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 193     Nigeria Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 194     Nigeria Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 195     Nigeria Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 196     Algeria Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030 

Table 197     Algeria Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030

Table 198     Algeria Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 199     Algeria Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 200     Algeria Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 201     Rest of MEA Non-Hodgkin Lymphoma Therapeutics Market Size, By Value (USD Billion), 2019–2030        

Table 202     Rest of MEA Non-Hodgkin Lymphoma Therapeutics Market Size, By Therapy Type, By Value (USD Billion), 2019–2030    

Table 203     Rest of MEA Non-Hodgkin Lymphoma Therapeutics Market Size, By Drug Class, By Value (USD Billion), 2019–2030

Table 204     Rest of MEA Non-Hodgkin Lymphoma Therapeutics Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 205     Rest of MEA Non-Hodgkin Lymphoma Therapeutics Market Size, By End User, By Value (USD Billion), 2019–2030

Table 206     AstraZeneca Plc Company Overview

Table 207     AstraZeneca Plc Financial Overview

Table 208     Bayer AG Company Overview

Table 209     Bayer AG Financial Overview

Table 210     F. Hoffmann-La Roche Ltd Company Overview

Table 211     F. Hoffmann-La Roche Ltd Financial Overview

Table 212     GlaxoSmithKline Plc Company Overview

Table 213     GlaxoSmithKline Plc Financial Overview

Table 214     Seagen Inc. Company Overview

Table 215     Seagen Inc. Financial Overview

Table 216     Takeda Pharmaceutical Company Limited Company Overview

Table 217     Takeda Pharmaceutical Company Limited Financial Overview

Table 218     Janssen Pharmaceuticals Inc. Company Overview

Table 219     Janssen Pharmaceuticals Inc. Financial Overview

Table 220     Eli Lilly and Company Company Overview

Table 221     Eli Lilly and Company Financial Overview

Table 222     Spectrum Pharmaceuticals Inc. Company Overview

Table 223     Spectrum Pharmaceuticals Inc. Financial Overview

Table 224     AbbVie Company Overview

Table 225     AbbVie Financial Overview

Table 224     Other Prominent Players Company Overview

Table 225     Other Prominent Players Financial Overview

 

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Note: Please share the corporate email address for faster response

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Global Non-Hodgkin Lymphoma Therapeutics Market size by value was estimated at USD 12.3 billion in 2023.
Ans: Global Non-Hodgkin Lymphoma Therapeutics Market by value is expected to grow at a CAGR of 8.90% during the forecast period between 2024 and 2030.
Ans: Global Non-Hodgkin Lymphoma Therapeutics Market size is forecast to reach a value of USD 20.5 billion by 2030.
Ans: The growth of Global Non-Hodgkin Lymphoma Therapeutics Market is primarily driven by rising prevalence, advancements in treatment options, increasing healthcare expenditure, and growing awareness about early diagnosis and innovative therapies.
Ans: The immunotherapy type segment accounts for the highest market share in Global Non-Hodgkin Lymphoma Therapeutics Market. 
array(1) {
  ["__ci_last_regenerate"]=>
  int(1732286089)
}